Immunic assumed with Outperform from Market Perform at Leerink

Leerink analyst Faisal Khurshid upgraded Immunic to Outperform from Market Perform with a $5 price target after assuming coverage of the name. The firm sees less risk for Vidofludimus Calcium than what it thinks the market implies, backed by an analysis of the biomarker data in progressive multiple sclerosis. Leerink says Immunic is one of its top picks based on the opportunity for VidoCa across multiple sclerosis.